Psychedelics & Cannabis

Cannabis use disorder and schizophrenia both peak in prevalence around the same age. Is there a cause-and-effect relationship?

Mark Viner, MD, shares his thoughts on the place cannabis holds in psychiatry and addressing the stigma cannabis faces.

As cannabis transitions from an illicit drug to a multi-billion-dollar industry, psychiatry faces both challenges and opportunities in exploring its therapeutic potential while balancing the risks.

Early phase 3 results show that a single dose of MM120 can rapidly reduce anxiety symptoms in GAD patients, with effects lasting up to 12 weeks.

Here are highlights from this week in Psychiatric Times, including conference updates and trial news.

With an FDA Breakthrough Therapy Designation, what are the next steps for MM-120?

MindMed has announced the first patient has been dosed in its phase 3 study Panorama.

New phase 3 data on CYB003 is coming. Learn more about the phase 3 pivotal program here.

Is there a way to separate the neuroplasticity and therapeutic effects from the hallucinatory and dissociative effects of traditional psychedelics?

Understanding the complex relationship between substance use and mental health is critical to providing thorough and well-informed evaluations. Let's take a look at the relationship between cannabis and criminal responsibility.

We asked our contributors at the 63rd meeting of the American College of Neuropsychopharmacology what they are excited about from 2024 and what they are looking forward to in 2025. Here's what they said.

With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?

New positive topline results from an open-label phase 2a study of IV psilocin benzoate in patients with major depressive disorder showed that the treatment delivers rapid, lasting antidepressant effects for up to 3 months following a single dose.

MindMed announced phase 3 study of psychedelic MM120 for Generalized Anxiety Disorder.

MindMed announced phase 3 of a trial testing a new treatment for generalized anxiety disorder is under way.

The presentation of catatonia can vary, making its management challenging, particularly in resource-limited settings in South Africa.

Post-hoc analysis of the ELEKT-D trial of ketamine and ECT for patients with treatment-resistant depression distinguishes between responders to the respective interventions.

How does ketamine-assisted psychotherapy help real world patients?

Psychiatrists are trying our ketamine-assisted psychotherapy in their clinical practices. What do patients think of this treatment?

Dr Miller continues her Ketamine Journal with a mini-group of 2 patients and a cofacilitator.

John Krystal, MD, explores the future of ketamine and psychedelics in psychiatry, shedding light on their potential to improve patient care by increasing options treatment options.

Should ketamine be used at all when FDA-approved Spravato is available and insurance will pay for it?

Psychedelics: we first must enlarge our knowledge of how these work, what clinical conditions should be targeted, and how different psychedelics compare to each other.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.